PURPOSE: This study was conducted to investigate the effect of Se supplementation on prostate cancer incidence in men at high risk for prostate cancer. METHODS: A Phase 3 randomized, double-blind, placebo-controlled clinical trial was conducted in 699 men at high risk for prostate cancer (prostate specific antigen (PSA) >4 ng/ml and/or suspicious digital rectal examination and/or PSA velocity >0.75 ng/ml/year), but with a negative prostate biopsy. Participants were randomized to receive daily oral placebo (N = 232), 200 µg selenium (N = 234), or 400 µg selenium (N = 233) as selenized yeast. They were followed every 6 months for up to 5 years. The time to diagnosis of prostate cancer was compared between treatment groups using the Cox proportional hazards model. RESULT: Compared to placebo, the hazard ratios [95% confidence intervals] for risk of developing prostate cancer in the selenium 200 µg/day or the selenium 400 µg/day group were 0.94 [0.52, 1.7] and 0.90 [0.48, 1.7], respectively. PSA velocity in the selenium arms was not significantly different from that observed in the placebo group (P = 0.18 and P = 0.17, respectively). CONCLUSION:Selenium supplementation appeared to have no effect on the incidence of prostate cancer in men at high risk. In conjunction with results of other studies, these data indicate that selenium supplementation may not have a role in prostate cancer chemoprevention.
RCT Entities:
PURPOSE: This study was conducted to investigate the effect of Se supplementation on prostate cancer incidence in men at high risk for prostate cancer. METHODS: A Phase 3 randomized, double-blind, placebo-controlled clinical trial was conducted in 699 men at high risk for prostate cancer (prostate specific antigen (PSA) >4 ng/ml and/or suspicious digital rectal examination and/or PSA velocity >0.75 ng/ml/year), but with a negative prostate biopsy. Participants were randomized to receive daily oral placebo (N = 232), 200 µg selenium (N = 234), or 400 µg selenium (N = 233) as selenized yeast. They were followed every 6 months for up to 5 years. The time to diagnosis of prostate cancer was compared between treatment groups using the Cox proportional hazards model. RESULT: Compared to placebo, the hazard ratios [95% confidence intervals] for risk of developing prostate cancer in the selenium 200 µg/day or the selenium 400 µg/day group were 0.94 [0.52, 1.7] and 0.90 [0.48, 1.7], respectively. PSA velocity in the selenium arms was not significantly different from that observed in the placebo group (P = 0.18 and P = 0.17, respectively). CONCLUSION:Selenium supplementation appeared to have no effect on the incidence of prostate cancer in men at high risk. In conjunction with results of other studies, these data indicate that selenium supplementation may not have a role in prostate cancer chemoprevention.
Authors: A M Algotar; M S Stratton; M J Xu; B L Dalkin; R B Nagle; C H Hsu; F R Ahmann; L C Clark; S P Stratton Journal: Nutr Cancer Date: 2011 Impact factor: 2.900
Authors: L C Clark; G F Combs; B W Turnbull; E H Slate; D K Chalker; J Chow; L S Davis; R A Glover; G F Graham; E G Gross; A Krongrad; J L Lesher; H K Park; B B Sanders; C L Smith; J R Taylor Journal: JAMA Date: 1996-12-25 Impact factor: 56.272
Authors: Amanda S Niskar; Daniel C Paschal; Stephanie M Kieszak; Katherine M Flegal; Barbara Bowman; Elaine W Gunter; James L Pirkle; Carol Rubin; Eric J Sampson; Michael McGeehin Journal: Biol Trace Elem Res Date: 2003-01 Impact factor: 3.738
Authors: Anna J Duffield-Lillico; Mary E Reid; Bruce W Turnbull; Gerald F Combs; Elizabeth H Slate; Lori A Fischbach; James R Marshall; Larry C Clark Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-07 Impact factor: 4.254
Authors: M S Stratton; M E Reid; G Schwartzberg; F E Minter; B K Monroe; D S Alberts; J R Marshall; F R Ahmann Journal: Anticancer Drugs Date: 2003-09 Impact factor: 2.248
Authors: A J Duffield-Lillico; B L Dalkin; M E Reid; B W Turnbull; E H Slate; E T Jacobs; J R Marshall; L C Clark Journal: BJU Int Date: 2003-05 Impact factor: 5.588
Authors: Marco Vinceti; Gabriele Dennert; Catherine M Crespi; Marcel Zwahlen; Maree Brinkman; Maurice P A Zeegers; Markus Horneber; Roberto D'Amico; Cinzia Del Giovane Journal: Cochrane Database Syst Rev Date: 2014-03-30
Authors: Amit M Algotar; Roxanna Behnejad; M Suzanne Stratton; Steven P Stratton Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-24 Impact factor: 4.254
Authors: Michael Mix; Anurag K Singh; Michael Tills; Shiva Dibaj; Adrienne Groman; Wainwright Jaggernauth; Youcef Rustum; Michael B Jameson Journal: World J Clin Oncol Date: 2015-10-10
Authors: John P Richie; Arun Das; Ana M Calcagnotto; Raghu Sinha; Wanda Neidig; Jiangang Liao; Eugene J Lengerich; Arthur Berg; Terryl J Hartman; Amy Ciccarella; Aaron Baker; Matthew G Kaag; Susan Goodin; Robert S DiPaola; Karam El-Bayoumy Journal: Cancer Prev Res (Phila) Date: 2014-06-17